SenesTech (NASDAQ:SNES) Announces Earnings Results

SenesTech (NASDAQ:SNES) released its earnings results on Tuesday. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01, Bloomberg Earnings reports. SenesTech had a negative return on equity of 186.65% and a negative net margin of 3,908.08%.

NASDAQ:SNES opened at $1.41 on Wednesday. The company has a current ratio of 3.83, a quick ratio of 2.76 and a debt-to-equity ratio of 0.07. The business’s 50 day moving average price is $1.50. SenesTech has a 52 week low of $0.55 and a 52 week high of $1.95. The company has a market cap of $38.72 million, a P/E ratio of -2.23 and a beta of 1.76.

Separately, ValuEngine raised SenesTech from a “hold” rating to a “buy” rating in a report on Friday, June 28th.

In other news, CEO Kenneth S. Siegel bought 696,296 shares of SenesTech stock in a transaction on Tuesday, July 16th. The shares were bought at an average price of $1.35 per share, with a total value of $939,999.60. Following the acquisition, the chief executive officer now directly owns 702,558 shares in the company, valued at approximately $948,453.30. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 10.91% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Virtu Financial LLC raised its position in shares of SenesTech by 87.4% during the 1st quarter. Virtu Financial LLC now owns 56,447 shares of the company’s stock worth $69,000 after purchasing an additional 26,322 shares during the period. Meitav Dash Investments Ltd. acquired a new stake in SenesTech in the 1st quarter valued at approximately $81,000. BlackRock Inc. acquired a new stake in SenesTech in the 2nd quarter valued at approximately $115,000. Bank of New York Mellon Corp acquired a new stake in SenesTech in the 2nd quarter valued at approximately $62,000. Finally, MRA Associates USA LLC acquired a new stake in SenesTech in the 2nd quarter valued at approximately $46,000. Institutional investors and hedge funds own 6.93% of the company’s stock.

About SenesTech

SenesTech, Inc develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.

See Also: P/E Growth (PEG)

Earnings History for SenesTech (NASDAQ:SNES)

Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with's FREE daily email newsletter.